Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

177Lu-DOTATATE peptide receptor radionuclide therapy: dose response in small intestinal neuroendocrine tumors.

Jahn U, Ilan E, Sandström M, Garske-Román U, Lubberink M, Sundin A.

Neuroendocrinology. 2019 Oct 10. doi: 10.1159/000504001. [Epub ahead of print]

PMID:
31597134
2.

Estimating the cold-induced brown adipose tissue glucose uptake rate measured by 18F-FDG PET using infrared thermography and water-fat separated MRI.

Andersson J, Lundström E, Engström M, Lubberink M, Ahlström H, Kullberg J.

Sci Rep. 2019 Aug 26;9(1):12358. doi: 10.1038/s41598-019-48879-7.

3.

Overeating saturated fat promotes fatty liver and ceramides compared to polyunsaturated fat: a randomized trial.

Rosqvist F, Kullberg J, Ståhlman M, Cedernaes J, Heurling K, Johansson HE, Iggman D, Wilking H, Larsson A, Eriksson O, Johansson L, Straniero S, Rudling M, Antoni G, Lubberink M, Orho-Melander M, Borén J, Ahlström H, Risérus U.

J Clin Endocrinol Metab. 2019 Aug 1. pii: jc.2019-00160. doi: 10.1210/jc.2019-00160. [Epub ahead of print]

PMID:
31369090
4.

PET med O-15-vatten påvisade myokard­ischemi där övrig utredning gick bet.

Magnusson P, Nordström J, Lubberink M, Mörner S, Sörensen J.

Lakartidningen. 2019 Jul 17;116. pii: FL4E. Swedish.

5.

Assessment of myocardial viability with [15O]water PET: A validation study in experimental myocardial infarction.

Grönman M, Tarkia M, Stark C, Vähäsilta T, Kiviniemi T, Lubberink M, Halonen P, Kuivanen A, Saunavaara V, Tolvanen T, Teuho J, Teräs M, Savunen T, Pietilä M, Ylä-Herttuala S, Roivainen A, Knuuti J, Saraste A.

J Nucl Cardiol. 2019 Jul 17. doi: 10.1007/s12350-019-01818-5. [Epub ahead of print]

PMID:
31317328
6.

Evaluation of quantitative CMR perfusion imaging by comparison with simultaneous 15O-water-PET.

Kero T, Johansson E, Engström M, Eggers KM, Johansson L, Ahlström H, Lubberink M.

J Nucl Cardiol. 2019 Jul 16. doi: 10.1007/s12350-019-01810-z. [Epub ahead of print]

PMID:
31313066
7.

Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68Ga-DOTATOC and 68Ga-DOTATATE.

Ilan E, Velikyan I, Sandström M, Sundin A, Lubberink M.

J Nucl Med. 2019 Jul 13. pii: jnumed.119.228072. doi: 10.2967/jnumed.119.228072. [Epub ahead of print]

PMID:
31302632
8.

Regularized reconstruction of digital time-of-flight 68Ga-PSMA-11 PET/CT for the detection of recurrent disease in prostate cancer patients.

Lindström E, Velikyan I, Regula N, Alhuseinalkhudhur A, Sundin A, Sörensen J, Lubberink M.

Theranostics. 2019 May 25;9(12):3476-3484. doi: 10.7150/thno.31970. eCollection 2019.

9.

Synaptic vesicle protein 2A as a potential biomarker in synaptopathies.

Heurling K, Ashton NJ, Leuzy A, Zimmer ER, Blennow K, Zetterberg H, Eriksson J, Lubberink M, Schöll M.

Mol Cell Neurosci. 2019 Jun;97:34-42. doi: 10.1016/j.mcn.2019.02.001. Epub 2019 Feb 20. Review.

10.

Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [18F]THK5317 PET.

Jonasson M, Wall A, Chiotis K, Leuzy A, Eriksson J, Antoni G, Nordberg A, Lubberink M.

Neuroimage Clin. 2019;22:101681. doi: 10.1016/j.nicl.2019.101681. Epub 2019 Jan 22.

11.

Altered Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Predict Whole-Body Insulin Resistance and may Contribute to the Development of Type 2 Diabetes: A Combined PET/MR Study.

Boersma GJ, Johansson E, Pereira MJ, Heurling K, Skrtic S, Lau J, Katsogiannos P, Panagiotou G, Lubberink M, Kullberg J, Ahlström H, Eriksson JW.

Horm Metab Res. 2018 Aug;50(8):e10. doi: 10.1055/a-0831-3620. Epub 2019 Jan 22.

PMID:
30669164
12.

Evaluation of zero-echo-time attenuation correction for integrated PET/MR brain imaging-comparison to head atlas and 68Ge-transmission-based attenuation correction.

Sousa JM, Appel L, Engström M, Papadimitriou S, Nyholm D, Larsson EM, Ahlström H, Lubberink M.

EJNMMI Phys. 2018 Oct 22;5(1):20. doi: 10.1186/s40658-018-0220-0.

13.

Z-score maps from low-dose 18F-FDG PET of the brain in neurodegenerative dementia.

Fällmar D, Lilja J, Danfors T, Kilander L, Iyer V, Lubberink M, Larsson EM, Sörensen J.

Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):239-246. eCollection 2018.

14.

Glucose metabolism in the brain in LMNB1-related autosomal dominant leukodystrophy.

Finnsson J, Lubberink M, Savitcheva I, Fällmar D, Melberg A, Kumlien E, Raininko R.

Acta Neurol Scand. 2019 Feb;139(2):135-142. doi: 10.1111/ane.13024. Epub 2018 Sep 25.

15.

Association between amygdala neurokinin-1 receptor availability and anxiety-related personality traits.

Hoppe JM, Frick A, Åhs F, Linnman C, Appel L, Jonasson M, Lubberink M, Långström B, Frans Ö, von Knorring L, Fredrikson M, Furmark T.

Transl Psychiatry. 2018 Aug 28;8(1):168. doi: 10.1038/s41398-018-0163-1.

16.

Quantification of 11C-PIB kinetics in cardiac amyloidosis.

Kero T, Sörensen J, Antoni G, Wilking H, Carlson K, Vedin O, Rosengren S, Wikström G, Lubberink M.

J Nucl Cardiol. 2018 Jul 23. doi: 10.1007/s12350-018-1349-x. [Epub ahead of print]

PMID:
30039218
17.

Non-invasive tri-modal visualisation via PET/SPECT/μCT of recombinant human bone morphogenetic protein-2 retention and associated bone regeneration: A proof of concept.

Hulsart-Billström G, Selvaraju RK, Estrada S, Lubberink M, Asplund V, Bergman K, Marsell R, Larsson S, Antoni G.

J Control Release. 2018 Sep 10;285:178-186. doi: 10.1016/j.jconrel.2018.07.012. Epub 2018 Jul 11.

18.

Altered Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Predict Whole-Body Insulin Resistance and may Contribute to the Development of Type 2 Diabetes: A Combined PET/MR Study.

Boersma GJ, Johansson E, Pereira MJ, Heurling K, Skrtic S, Lau J, Katsogiannos P, Panagiotou G, Lubberink M, Kullberg J, Ahlström H, Eriksson JW.

Horm Metab Res. 2018 Aug;50(8):627-639. doi: 10.1055/a-0643-4739. Epub 2018 Jul 12.

PMID:
30001566
19.

Cerebral serotonin transporter measurements with [11C]DASB: A review on acquisition and preprocessing across 21 PET centres.

Nørgaard M, Ganz M, Svarer C, Feng L, Ichise M, Lanzenberger R, Lubberink M, Parsey RV, Politis M, Rabiner EA, Slifstein M, Sossi V, Suhara T, Talbot PS, Turkheimer F, Strother SC, Knudsen GM.

J Cereb Blood Flow Metab. 2019 Feb;39(2):210-222. doi: 10.1177/0271678X18770107. Epub 2018 Apr 13.

PMID:
29651896
20.

Evaluation of Penalized-Likelihood Estimation Reconstruction on a Digital Time-of-Flight PET/CT Scanner for 18F-FDG Whole-Body Examinations.

Lindström E, Sundin A, Trampal C, Lindsjö L, Ilan E, Danfors T, Antoni G, Sörensen J, Lubberink M.

J Nucl Med. 2018 Jul;59(7):1152-1158. doi: 10.2967/jnumed.117.200790. Epub 2018 Feb 15.

21.

Development of a clinically feasible [11C]PE2I PET method for differential diagnosis of parkinsonism using reduced scan duration and automated reference region extraction.

Jonasson M, Appel L, Danfors T, Nyholm D, Askmark H, Frick A, Engman J, Furmark T, Sörensen J, Lubberink M.

Am J Nucl Med Mol Imaging. 2017 Dec 20;7(6):263-274. eCollection 2017.

22.

Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease.

Leuzy A, Rodriguez-Vieitez E, Saint-Aubert L, Chiotis K, Almkvist O, Savitcheva I, Jonasson M, Lubberink M, Wall A, Antoni G, Nordberg A.

Alzheimers Dement. 2018 May;14(5):652-663. doi: 10.1016/j.jalz.2017.11.008. Epub 2017 Dec 19.

23.

Calculation of left ventricular volumes and ejection fraction from dynamic cardiac-gated 15O-water PET/CT: 5D-PET.

Nordström J, Kero T, Harms HJ, Widström C, Flachskampf FA, Sörensen J, Lubberink M.

EJNMMI Phys. 2017 Nov 14;4(1):26. doi: 10.1186/s40658-017-0195-2.

24.

Whole-Body Imaging of Tissue-specific Insulin Sensitivity and Body Composition by Using an Integrated PET/MR System: A Feasibility Study.

Johansson E, Lubberink M, Heurling K, Eriksson JW, Skrtic S, Ahlström H, Kullberg J.

Radiology. 2018 Jan;286(1):271-278. doi: 10.1148/radiol.2017162949. Epub 2017 Aug 25.

PMID:
28846496
25.

Quantification, improvement, and harmonization of small lesion detection with state-of-the-art PET.

van der Vos CS, Koopman D, Rijnsdorp S, Arends AJ, Boellaard R, van Dalen JA, Lubberink M, Willemsen ATM, Visser EP.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):4-16. doi: 10.1007/s00259-017-3727-z. Epub 2017 Jul 8. Review.

26.

Quantitative positron emission tomography in brain research.

Heurling K, Leuzy A, Jonasson M, Frick A, Zimmer ER, Nordberg A, Lubberink M.

Brain Res. 2017 Sep 1;1670:220-234. doi: 10.1016/j.brainres.2017.06.022. Epub 2017 Jun 23. Review.

PMID:
28652218
27.

Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases.

Wassberg C, Lubberink M, Sörensen J, Johansson S.

EJNMMI Res. 2017 Dec;7(1):42. doi: 10.1186/s13550-017-0289-9. Epub 2017 May 15.

28.

Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.

Chiotis K, Saint-Aubert L, Rodriguez-Vieitez E, Leuzy A, Almkvist O, Savitcheva I, Jonasson M, Lubberink M, Wall A, Antoni G, Nordberg A.

Mol Psychiatry. 2018 Jul;23(7):1666-1673. doi: 10.1038/mp.2017.108. Epub 2017 May 16.

PMID:
28507319
29.

Studies of a Next-Generation Silicon-Photomultiplier-Based Time-of-Flight PET/CT System.

Hsu DFC, Ilan E, Peterson WT, Uribe J, Lubberink M, Levin CS.

J Nucl Med. 2017 Sep;58(9):1511-1518. doi: 10.2967/jnumed.117.189514. Epub 2017 Apr 27.

30.

Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising.

Golla SSV, Lubberink M, van Berckel BNM, Lammertsma AA, Boellaard R.

EJNMMI Res. 2017 Dec;7(1):36. doi: 10.1186/s13550-017-0284-1. Epub 2017 Apr 21.

31.

Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study.

Bodén R, Persson J, Wall A, Lubberink M, Ekselius L, Larsson EM, Antoni G.

Transl Psychiatry. 2017 Mar 7;7(3):e1050. doi: 10.1038/tp.2017.11.

32.

[11C]5-hydroxy-tryptophan PET for Assessment of Islet Mass During Progression of Type 2 Diabetes.

Carlbom L, Espes D, Lubberink M, Martinell M, Johansson L, Ahlström H, Carlsson PO, Korsgren O, Eriksson O.

Diabetes. 2017 May;66(5):1286-1292. doi: 10.2337/db16-1449. Epub 2017 Feb 28.

33.

Quantitative myocardial blood flow imaging with integrated time-of-flight PET-MR.

Kero T, Nordström J, Harms HJ, Sörensen J, Ahlström H, Lubberink M.

EJNMMI Phys. 2017 Dec;4(1):1. doi: 10.1186/s40658-016-0171-2. Epub 2017 Jan 6.

34.

Parametric Net Influx Rate Images of 68Ga-DOTATOC and 68Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast.

Ilan E, Sandström M, Velikyan I, Sundin A, Eriksson B, Lubberink M.

J Nucl Med. 2017 May;58(5):744-749. doi: 10.2967/jnumed.116.180380. Epub 2016 Oct 27.

35.

Validation of true low-dose 18F-FDG PET of the brain.

Fällmar D, Lilja J, Kilander L, Danfors T, Lubberink M, Larsson EM, Sörensen J.

Am J Nucl Med Mol Imaging. 2016 Sep 22;6(5):269-276. eCollection 2016.

36.

Reduced serotonin synthesis and regional cerebral blood flow after anxiolytic treatment of social anxiety disorder.

Frick A, Åhs F, Appel L, Jonasson M, Wahlstedt K, Bani M, Merlo Pich E, Bettica P, Långström B, Lubberink M, Fredrikson M, Furmark T.

Eur Neuropsychopharmacol. 2016 Nov;26(11):1775-1783. doi: 10.1016/j.euroneuro.2016.09.004. Epub 2016 Sep 15.

PMID:
27642077
37.

Alterations in the serotonergic and substance P systems in posttraumatic stress disorder.

Frick A, Åhs F, Palmquist ÅM, Pissiota A, Wallenquist U, Fernandez M, Jonasson M, Appel L, Frans Ö, Lubberink M, Furmark T, von Knorring L, Fredrikson M.

Mol Psychiatry. 2016 Oct;21(10):1323. doi: 10.1038/mp.2016.159. No abstract available.

PMID:
27640369
38.

Blood Flow Quantitation by Positron Emission Tomography During Selective Antegrade Cerebral Perfusion.

Tovedal T, Lubberink M, Morell A, Estrada S, Golla SS, Myrdal G, Lindblom RP, Thelin S, Sörensen J, Antoni G, Lennmyr F.

Ann Thorac Surg. 2017 Feb;103(2):610-616. doi: 10.1016/j.athoracsur.2016.06.029. Epub 2016 Sep 1.

PMID:
27592601
39.
40.

Pancreatic perfusion and subsequent response to glucose in healthy individuals and patients with type 1 diabetes.

Carlbom L, Espes D, Lubberink M, Eriksson O, Johansson L, Jansson L, Korsgren O, Ahlström H, Carlsson PO.

Diabetologia. 2016 Sep;59(9):1968-72. doi: 10.1007/s00125-016-4016-2. Epub 2016 Jun 16.

PMID:
27306617
41.

[(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A.

Estrada S, Lubberink M, Thibblin A, Sprycha M, Buchanan T, Mestdagh N, Kenda B, Mercier J, Provins L, Gillard M, Tytgat D, Antoni G.

Nucl Med Biol. 2016 Jun;43(6):325-32. doi: 10.1016/j.nucmedbio.2016.03.004. Epub 2016 Mar 17.

PMID:
27260773
42.

Noninvasive Quantification of Myocardial 11C-Meta-Hydroxyephedrine Kinetics.

Harms HJ, Huisman MC, Rijnierse MT, Greuter H, Hsieh YL, de Haan S, Schuit RC, Knaapen P, Lubberink M, Lammertsma AA.

J Nucl Med. 2016 Sep;57(9):1376-81. doi: 10.2967/jnumed.115.167437. Epub 2016 May 26.

43.

Feasibility of (68)Ga-labeled Siglec-9 peptide for the imaging of acute lung inflammation: a pilot study in a porcine model of acute respiratory distress syndrome.

Retamal J, Sörensen J, Lubberink M, Suarez-Sipmann F, Borges JB, Feinstein R, Jalkanen S, Antoni G, Hedenstierna G, Roivainen A, Larsson A, Velikyan I.

Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):18-31. eCollection 2016.

44.

Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.

Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Jonasson M, Eriksson J, Lubberink M, Almkvist O, Wall A, Antoni G, Nordberg A.

Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1686-99. doi: 10.1007/s00259-016-3363-z. Epub 2016 Mar 21.

45.

Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.

Sandström M, Lindskog K, Velikyan I, Wennborg A, Feldwisch J, Sandberg D, Tolmachev V, Orlova A, Sörensen J, Carlsson J, Lindman H, Lubberink M.

J Nucl Med. 2016 Jun;57(6):867-71. doi: 10.2967/jnumed.115.169342. Epub 2016 Feb 9.

46.

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.

Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandström M, Lubberink M, Olofsson H, Carlsson J, Lindman H.

Theranostics. 2016 Jan 1;6(2):262-71. doi: 10.7150/thno.13502. eCollection 2016.

47.

Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.

Jonasson M, Wall A, Chiotis K, Saint-Aubert L, Wilking H, Sprycha M, Borg B, Thibblin A, Eriksson J, Sörensen J, Antoni G, Nordberg A, Lubberink M.

J Nucl Med. 2016 Apr;57(4):574-81. doi: 10.2967/jnumed.115.158519. Epub 2016 Jan 21.

48.

Use of 5-Hydroxytryptophan Labeled With Carbon 11 in Social Anxiety Disorder--Reply.

Frick A, Lubberink M, Furmark T.

JAMA Psychiatry. 2016 Feb;73(2):177-8. doi: 10.1001/jamapsychiatry.2015.2751. No abstract available.

PMID:
26720843
49.

Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting.

Altai M, Perols A, Tsourma M, Mitran B, Honarvar H, Robillard M, Rossin R, ten Hoeve W, Lubberink M, Orlova A, Karlström AE, Tolmachev V.

J Nucl Med. 2016 Mar;57(3):431-6. doi: 10.2967/jnumed.115.162248. Epub 2015 Dec 10.

50.

Overlapping expression of serotonin transporters and neurokinin-1 receptors in posttraumatic stress disorder: a multi-tracer PET study.

Frick A, Åhs F, Palmquist ÅM, Pissiota A, Wallenquist U, Fernandez M, Jonasson M, Appel L, Frans Ö, Lubberink M, Furmark T, von Knorring L, Fredrikson M.

Mol Psychiatry. 2016 Oct;21(10):1400-7. doi: 10.1038/mp.2015.180. Epub 2015 Dec 1.

PMID:
26619809

Supplemental Content

Loading ...
Support Center